We have just started the 2nd day of the #ILEP2025 Congress in Warsaw. The first session is dedicated to #statin #therapy💪 #ArmanPostadzhiyan #ZlatkoFras @GaniBajraktari @stanislawsurma @ExpertLipid

Why #upfront #lipid lowering combination #therapy should to be a GOLD standard in the management of #patients with high and very high #cardiovascular #disease #risk? Why we need to change the paradigm of short-term #risk #stratification (to 👉 lifetime risk stratification) and

Very important meeing pf EU-RO Forum on #Diabetes and its #complications in Bucharest organized by Prof. Anca Stoian. Thanks for the Invitation💪

On Thursday I was in Ljubljana at the Transcutaneous Contemporary Interventions-Coronaries (#TCICoronaries) Meeting, where within interventional cardiologists I presented the newest data on the #upfront lipid lowering combination #therapy in #ACS patients. Our data from the

Our recent, just published in #EHJOpen journal by the @escardio , largest ever #metaanalysis on #FH #children #patients, showed not only a large efficacy of #lipid lowering #therapy #LLT, especially combination one, but it also clearly showed that #statin/lipid lowering therapy

A look to the past – what has had the biggest impact on lipids in the last four decades? A personal perspective https://t.co/2ch0GDMjmd

❗️❗️❗️

IMPORTANT from the new issue of @ArchMedSci: 2024 Polish #recommendations for the #management of #familial #hypercholesterolemia #FH in #children and #adolescents. The most important recommendations: 👉 It is advisable to use direct #LDL #cholesterol #measurement for improved

The results of our data from the #PMMHRI-#LPA #Registry and #STAR-#LPA study that were presented at the @escardio #congress in London again beautifully summarized in the @MSN. Thanks! https://t.co/GLeYgzq9Jm

Important paper on the trends on #aspirin use in primary and secondary prevention in US. The trend is stable in 2ndary prevention based on guidelines, but it was significantly reduced (what is not a surprise) in primary prevention especially in older patients >70 years of age for

Feel invited to join us at the 4th World Congress of Clinical Lipidology in Vienna! @lipiddoctor

Pamietam nasza najwieksza na świecie meta-analizę (640,000 osób), która oceniała wpływ produktów mlecznych na zgon bez względu na przyczynę, zgony sercowo-naczyniowe i inne punkty końcowe. Wówczas wykazaliśmy, ze produkty pochodzenia mlecznego w diecie maja korzystny wpływ na

Pewnie pamiętacie nasza analizę, która była jedna z najbadziej cytowanych w światowych mediach (@altmetric score 6280) prac w 2023 roku o roli kroków w wydłużaniu życia, w której powiedzieliśmy, ze dla osób względnie zdrowych, bez choroby sercowo-naczyniowej korzystny efekt

@Amit04Ag @ArchMedSci @stanislawsurma @DzidaGrzegorz @AndrzejGrzybow @JacekRysz @UniOpole @ICZMP @DiabeticEyes @DiabeticR @AmDiabetesAssn @IntDiabetesFed

Our Expert Opinion article on the extended indications for #fenofibrate in prevention of #cardiovascular #complications, and specifically #retinopathy is a cover article of the new issue of the @ArchMedSci. This was a tremendous work of the experts representing different

Prof. @maciejbanach: fakultatywność całkowicie wypacza ideę #edukacjazdrowotna. Jak mamy być skuteczni w leczeniu społeczeństwa, skoro go nie edukujemy? @MEN_GOVPL @barbaraanowacka @Leszczyna @MZ_GOV_PL 👉 https://t.co/th2zPlhpNK

https://t.co/ljSYsqeDJy

Amazing news ‼️ Our joint analysis on the role of endothelial IGFBP6 in the suppression of vascular inflammation and atherosclerosis has just been released in the @Nature Cardiovascular Research 💪 Within this analysis we identify insulin-like growth factor binding protein 6

Another paper affiliated from the Faculty of Medicine of @KUL_Lublin on the recent advances in primary and secondary #cardiovascular #prevention. We discuss here the concept of the #lifetime #CVD #riskstratification comparing different available #risk #scores. For the first

Have you already booked your time for the 10th Anniversary Meeting of the International Lipid Expert Panel @ExpertLipid ? 💪 Stay Tuned for the next info🥰